Immunomedics to present CEA-Scan data

Article

Monoclonal antibody imaging agent developer Immunomedics of MorrisPlains, NJ, said this month that the Food and Drug Administrationhas scheduled a date for the company to present data from clinicaltrials for its CEA-Scan colorectal cancer imaging agent.

Monoclonal antibody imaging agent developer Immunomedics of MorrisPlains, NJ, said this month that the Food and Drug Administrationhas scheduled a date for the company to present data from clinicaltrials for its CEA-Scan colorectal cancer imaging agent. The moveis a follow-up to an action last year in which the FDA said CEA-Scan'sproduct license application was not approvable in its form atthe time (SCAN 6/1/94).

The FDA has scheduled the meeting for Oct. 17, at which timethe two parties will discuss the FDA's request for clarificationof the data and analyses Immunomedics provided the agency in responseto the not-approvable letter. The regulatory status of CEA-Scan'sPLA for colorectal cancer imaging is not-yet-approvable, accordingto Immunomedics.

In other Immunomedics news, the company reported progress onseveral other agents it is developing. It said last week thatphase-III clinical trials for its LeukoScan infectious diseaseimaging agent have demonstrated clear diagnostic utility for imagingbone infections. Other trials have supported the use of CEA-Scanin breast cancer imaging.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.